Ke Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ke Liu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Hongchang Li
Shenzhen Institute of Advanced Technology 7 Guangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials Chinese Academy of Sciences, Shenzhen, China
23 shared publications - Binyu Zhang
Southern University of Science and Technology 1 Department of Biochemistry, SUSTech Homeostatic Medicine Institute, School of Medicine Shenzhen, China
22 shared publications - Fan Yang
Shenzhen People’s Hospital 6 Department of General Surgery, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Center for Geriatrics The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China
22 shared publications - Guanyin Huang
Southern University of Science and Technology 1 Department of Biochemistry, SUSTech Homeostatic Medicine Institute, School of Medicine Shenzhen, China
22 shared publications - Hailiang Hu
Department of Biochemistry, SUSTech Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen, China
22 shared publications - Hao Yu
Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China
22 shared publications
Latest Publications
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S6. Senescent features are diminished in established lung metastasis derived from CTTN KD-induced senescent CTCs
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S6. Senescent features are diminished in established lung metastasis derived from CTTN KD-induced senescent CTCs
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S17 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S17. The MEK inhibitor, cobimetinib, sensitizes senescent CTCs to apoptosis
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S17 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S17. The MEK inhibitor, cobimetinib, sensitizes senescent CTCs to apoptosis
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S7. Transcriptomic and proteomic changes of melanoma cells upon cortactin depletion
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S7. Transcriptomic and proteomic changes of melanoma cells upon cortactin depletion
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S3. Single-cell RNA-seq of early CTC cultures reveals heterogenous expression of CTTN in single CTCs that are inversely correlated with the senescence state
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S3. Single-cell RNA-seq of early CTC cultures reveals heterogenous expression of CTTN in single CTCs that are inversely correlated with the senescence state
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S4. Cortactin depletion inhibits melanoma tumorigenesis and metastasis
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S4. Cortactin depletion inhibits melanoma tumorigenesis and metastasis
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S8. CTTN KD-induced cellular senescence and growth suppression is p53-dependent
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S8. CTTN KD-induced cellular senescence and growth suppression is p53-dependent
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S13 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S13. Cortactin depletion results in mtROS elevation
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S13 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S13. Cortactin depletion results in mtROS elevation
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S14 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S14. Cortactin KD induces time-course dependent p53 activation and mtROS elevation
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S14 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S14. Cortactin KD induces time-course dependent p53 activation and mtROS elevation
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Table S2, antibody infomation
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Table S2, antibody infomation
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S10. KD CTTN leads to aberrant Rab7-positive late endosomal aggregates with mTOR co-localization and activation
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S10. KD CTTN leads to aberrant Rab7-positive late endosomal aggregates with mTOR co-localization and activation